Eledon pharmaceuticals reports second quarter 2023 operating and financial results

Ninth patient dosed in ongoing phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation; updated clinical data expected in the fourth quarter

ELDN Ratings Summary

ELDN Quant Ranking